Miltenyi Biotec, a global biotechnology firm and MiLaboratories, a company specialising in RNA immune technologies, have partnered to develop next generation therapies in the field of immunology.
This collaboration combines MiLaboratories' RNA kit technology for immune sequencing with Miltenyi Biotec's robust production and commercialisation capabilities.
The terms
Under this agreement, MiLaboratories will grant exclusive rights to its RNA kits immune sequencing technology to Miltenyi Biotec, which has been instrumental in advancing research and development in the field of immunology and personalised medicine.
Miltenyi Biotec will leverage its global reach and expertise in biotechnology to produce and commercialise these kits, making them available to researchers and clinicians worldwide.
A cornerstone of this partnership is the integration of MiLaboratories' software solutions — MiXCR and Platforma— into Miltenyi Biotec's offerings. These software platforms are equipped for next-generation sequencing (NGS) data analysis, providing powerful, user-friendly tools for genomic data interpretation.
Customers purchasing RNA kits from Miltenyi Biotec will now have access to MiXCR and Platforma, enhancing their research capabilities and efficiency.
"This partnership is a significant milestone in our mission to accelerate the development of next-generation therapies," said Stan Poslavsky, CEO of MiLaboratories. "By combining our RNA technologies and software platforms with Miltenyi Biotec's manufacturing and commercial strengths, we are poised to make a substantial impact in the field of genomics and personalised medicine."
This partnership is expected to accelerate the pace of discovery and development in the field of genomics, offering researchers and clinicians new tools to explore the complexities of genetic information and foster the development of innovative therapies.
